|Articles|September 23, 2022
Antibody-based drug discovery at the speed of light
Author(s)Curia
The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
3
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
4
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
5